Daunorubicin

證據等級: L5

預測適應症: 10 個

Daunorubicin: From Acute Leukemia to Hodgkin’s Lymphoma

One-Sentence Summary

Daunorubicin is a classic anthracycline antibiotic originally approved for the treatment of acute leukemia (AML and ALL), where it acts as a cytotoxic backbone agent in induction chemotherapy. The TxGNN model predicts it may be effective for Hodgkin’s Lymphoma, with 50 clinical trials and 20 publications currently supporting this direction. While direct Daunorubicin data in Hodgkin’s Lymphoma remains limited, robust Phase 3 evidence from the broader anthracycline drug class provides a strong mechanistic and clinical foundation for this prediction.

Quick Overview

Item	Content
Original Indication	Acute leukemia (AML / ALL)
Predicted New Indication	Hodgkin’s Lymphoma
TxGNN Prediction Score	99.81%
Evidence Level	L2
India Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on established pharmacology, Daunorubicin is an anthracycline antibiotic that exerts cytotoxic effects primarily through intercalation into the DNA double helix and inhibition of topoisomerase II — an enzyme essential for DNA replication and repair. This disrupts DNA synthesis, triggers DNA strand breaks, and ultimately induces apoptosis in rapidly dividing cells. It was originally approved for the treatment of acute leukemia, where its activity in highly proliferative hematologic malignancies is well documented.

Hodgkin’s Lymphoma (HL) is likewise a hematologic malignancy arising from clonal B-lymphocytes (Reed–Sternberg cells), characterized by rapid cellular proliferation — precisely the biological substrate that anthracyclines target. The mechanistic parallel between leukemia and HL is direct: both are highly chemosensitive lymphoid malignancies driven by DNA replication. Indeed, Doxorubicin (the structural analogue of Daunorubicin within the same anthracycline class) forms the backbone of the ABVD and AVD regimens, which are the current standard of care for HL. Daunorubicin shares the same core pharmacophore and mode of action as Doxorubicin, differing only in a minor side-chain modification.

Direct supporting evidence for Daunorubicin in lymphoma appears in early clinical literature: PMID 9387047 (1997) evaluated liposomal Daunorubicin (DaunoXome) in 19 patients with relapsed or refractory lymphoma, demonstrating objective responses at higher dose schedules with a manageable cardiac safety profile. PMID 378369 (1979) provides an early analytical comparison of Daunorubicin and Doxorubicin across cancer types, confirming overlapping therapeutic activity. The TxGNN knowledge graph prediction (score 99.81%) therefore reflects a biologically coherent inference grounded in both drug-class clinical success and pharmacological similarity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05922904	Phase 2	Active, Not Recruiting	25	BV + Pembrolizumab + Doxorubicin + Dacarbazine in Stage II bulky or Stage III/IV classic HL; evaluates PET-adapted de-escalation
NCT04685616	Phase 3	Recruiting	1,042	RADAR trial: ABVD vs A2VD ± ISRT in untreated Stage IA/IIA HL; landmark Phase 3 with PET response-adapted design
NCT06745076	Phase 2	Recruiting	125	PRECISE-HL: ctDNA-guided personalised reduction of Nivolumab + Doxorubicin + Vinblastine + Dacarbazine intensity in advanced HL
NCT00822120	Phase 2	Completed	371	Response-adapted therapy for Stage III–IV HL using interim FDG-PET; tested escalation to BEACOPP for PET-positive patients
NCT02797717	—	Recruiting	2,200	EuroNet-C1: International multicentre trial reducing radiotherapy in classical HL in children and adolescents
NCT00005578	Phase 3	Completed	219	Paediatric advanced-stage HL: combination chemotherapy ± dexrazoxane (cardioprotection); confirmed anthracycline necessity
NCT00302003	Phase 3	Completed	287	Low-risk paediatric Hodgkin’s disease: chemotherapy before radiation and/or additional chemo; established anthracycline backbone
NCT06831370	Phase 4	Recruiting	124	India-specific — BV + AVD (Doxorubicin + Vinblastine + Dacarbazine) in Indian patients with untreated Stage 3/4 classical HL; includes cardiac monitoring (ECHO, PFT)
NCT02191930	Phase 2	Completed	70	BV or B-CAP in older patients with newly diagnosed classical HL; ORR and 3-year PFS as co-primary endpoints
NCT01868451	—	Active, Not Recruiting	118	BV + AVD in early-stage unfavourable-risk HL; evaluates feasibility of omitting bleomycin and radiation

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39413375	2024	RCT	N Engl J Med	Nivolumab + AVD (Doxorubicin + Vinblastine + Dacarbazine) vs ABVD in advanced classic HL; nivolumab combination improved PFS while maintaining safety
35830649	2022	RCT follow-up	N Engl J Med	5-year follow-up of A+AVD vs ABVD in Stage III/IV HL; confirmed long-term overall survival benefit with BV-augmented Doxorubicin regimen
27332902	2016	RCT	N Engl J Med	PET-CT interim response-adapted strategy in advanced HL; escalation to BEACOPP for interim PET-positive patients improved outcomes
20818855	2010	RCT	N Engl J Med	4-arm randomised trial comparing chemotherapy intensity and radiation dose in early-stage favourable HL; established anthracycline minimisation principles
9387047	1997	Phase I/II	Invest New Drugs	Direct Daunorubicin evidence: Liposomal Daunorubicin (DaunoXome) in 19 relapsed/refractory lymphoma patients; 1 CR + 2 PR at 120 mg/m² with manageable cardiac toxicity
36271128	2022	Retrospective cohort	Sci Rep	Interim FDG-PET/CT predictive value in 245 HL patients treated with ABVD; interim PET-2 negativity strongly correlated with long-term disease-free survival
378369	1979	Review	Cancer Treat Rep	Direct Daunorubicin evidence: Comparative analysis of Daunorubicin and Adriamycin (Doxorubicin) across cancer types; documented overlapping therapeutic roles in haematologic malignancies
28365830	2017	Review	Curr Oncol Rep	Current role of radiotherapy in early-stage HL within risk-adapted and response-adapted treatment frameworks; context for non-anthracycline adjuncts
14584273	2003	Review	Gan To Kagaku Ryoho	Overview of haematologic tumour chemotherapy development; explicitly discusses Daunorubicin’s role in AML and the evolution of ABVD as the HL standard
21774715	2011	Editorial	N Engl J Med	“Hodgkin’s lymphoma — the great teacher”: landmark perspective on how HL shaped modern oncology, including the central role of anthracycline-containing combination regimens

Cytotoxicity

Daunorubicin is a conventional cytotoxic anthracycline chemotherapy agent.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Anthracycline class (intercalating agent / topoisomerase II inhibitor)
Myelosuppression Risk	High — severe neutropenia, thrombocytopenia, and anaemia are expected dose-limiting toxicities; nadir typically occurs at 10–14 days post-infusion
Emetogenicity Classification	Moderate to high emetogenicity (5-HT₃ antagonist + dexamethasone prophylaxis recommended)
Monitoring Items	CBC with differential (pre-cycle and at nadir), liver function tests, renal function, serum uric acid (tumour lysis risk), and serial cardiac monitoring (LVEF by ECHO or MUGA at baseline and after cumulative dose thresholds)
Handling Protection	Must follow cytotoxic drug safe handling regulations — closed system drug transfer devices, protective PPE, designated preparation area required

Cardiac Toxicity Note: Daunorubicin carries a cumulative dose-dependent cardiotoxicity risk (dilated cardiomyopathy, congestive heart failure). Cumulative lifetime dose should be carefully tracked. Dexrazoxane should be considered as a cardioprotectant in settings with high cumulative anthracycline exposure. PMID 9387047 noted no clinical cardiac deterioration with liposomal Daunorubicin at 120 mg/m², suggesting formulation may influence cardiac risk profile.

Safety Considerations

Drug Interactions (387 interactions identified; representative selection below):

Interacting Drug	Severity	Clinical Relevance
Cisapride	Major	Risk of QT prolongation and potentially fatal arrhythmia; avoid combination
Dolasetron	Major	Additive QT prolongation risk; use alternative antiemetics (ondansetron with monitoring)
Papaverine	Major	Additive QT prolongation; avoid co-administration
Deferiprone	Major	Additive myelosuppression risk; avoid concurrent use during chemotherapy cycles
Macimorelin	Major	Potential QT prolongation interaction; avoid if cardiac monitoring unavailable
Clarithromycin	Moderate	CYP3A4 inhibition may increase daunorubicin exposure; monitor for enhanced toxicity
Ondansetron	Moderate	Additive QT prolongation; ECG monitoring recommended when co-administered
Levofloxacin	Moderate	Additive QT prolongation risk; prefer alternative antibiotics
Granisetron / Palonosetron / Rolapitant	Moderate	QT prolongation; balance antiemetic benefit vs. cardiac risk with ECG monitoring
Eliglustat	Moderate	P-gp/CYP2D6 interaction may alter drug levels

Total DDI database entries: 387. The predominant interaction theme is QT prolongation (relevant for pre-existing cardiac conditions or concurrent QT-prolonging antiemetics) and additive myelosuppression. A full medication reconciliation is mandatory before each treatment cycle.

India Market Information

Daunorubicin is currently not registered or marketed in India (0 active authorisations in the CDSCO database). Clinical use would require individual patient import approval or compassionate use authorisation. This absence of a local regulatory filing is a key consideration for any market development strategy.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction score of 99.81% for Hodgkin’s Lymphoma is mechanistically well-supported: Daunorubicin and Doxorubicin share the same anthracycline pharmacophore, and Doxorubicin-based regimens (ABVD, AVD, A+AVD) represent the global standard of care for HL across multiple completed Phase 3 trials. Direct evidence for Daunorubicin in lymphoma exists (PMID 9387047, PMID 378369), and the class-level evidence is strong. However, drug-specific Phase 3 data for Daunorubicin in HL is absent, and the drug is not currently registered in India.

To proceed, the following is needed:

MOA documentation: Retrieve complete mechanism of action and pharmacokinetic data from DrugBank API or package insert (remediation for DG002) to support regulatory submissions
India package insert safety data: Download and parse the reference country (e.g., US, EU) prescribing information to complete the safety profile — including full black-box warnings, contraindications, and dose-limiting toxicity thresholds (remediation for DG001)
Head-to-head comparison with Doxorubicin: Conduct a structured literature review to determine whether Daunorubicin offers any clinical advantage (e.g., liposomal formulation reducing cardiac toxicity per PMID 9387047) over Doxorubicin in HL, particularly for patient populations with pre-existing cardiac risk
Regulatory pathway assessment: Evaluate CDSCO requirements for new drug application or import licence for Daunorubicin in India, referencing existing approvals in US/EU (Cerubidine, DaunoXome)
Cardiac safety monitoring plan: Design a prospective cardiac monitoring protocol (baseline ECHO, serial LVEF assessments, cumulative dose ceiling) prior to any clinical study initiation
QT risk management protocol: Given 5 Major DDIs involving QT prolongation, develop a medication restriction list and ECG monitoring schedule for co-administered drugs in any investigator-initiated study

This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.